|
JP5658230B2
(ja)
|
2009-04-13 |
2015-01-21 |
インサーム（インスティテュート ナショナル デ ラ セント エ ドゥ ラ ルシェルシュ メディカル） |
Ｈｐｖ粒子およびその使用
|
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
EP3517130B1
(en)
|
2013-09-18 |
2022-03-30 |
Aura Biosciences, Inc. |
Method of producing photosensitive molecules
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
RU2717984C2
(ru)
|
2013-11-21 |
2020-03-27 |
ЮСиЭл БИЗНЕС ЛТД |
Клетка
|
|
WO2015084513A1
(en)
|
2013-12-06 |
2015-06-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
|
PL3083671T3
(pl)
|
2013-12-20 |
2021-03-22 |
Fred Hutchinson Cancer Center |
Znakowane chimeryczne cząsteczki efektorowe i ich receptory
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US20230027993A1
(en)
|
2014-03-05 |
2023-01-26 |
Autolus Limited |
Methods
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
RU2016143389A
(ru)
|
2014-04-10 |
2018-05-15 |
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) |
Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
|
|
SG11201609118RA
(en)
|
2014-05-15 |
2016-11-29 |
Univ Singapore |
Modified natural killer cells and uses thereof
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
AU2015367317A1
(en)
*
|
2014-12-17 |
2017-06-01 |
Cellectis |
Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
|
|
KR102376242B1
(ko)
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
WO2016123143A1
(en)
*
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
CN107406516B
(zh)
|
2015-01-26 |
2021-11-23 |
塞勒克提斯公司 |
用于癌症免疫治疗的抗CLL1特异性单链嵌合抗原受体(scCAR)
|
|
EP4134430A1
(en)
|
2015-02-06 |
2023-02-15 |
National University of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
|
CA2977106A1
(en)
*
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
HUE059218T2
(hu)
*
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
|
US10786549B2
(en)
|
2015-04-23 |
2020-09-29 |
Baylor College Of Medicine |
CD5 chimeric antigen receptor for adoptive T cell therapy
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507108D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
WO2016176652A2
(en)
*
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
*
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
US9574014B2
(en)
*
|
2015-05-15 |
2017-02-21 |
City Of Hope |
Chimeric antigen receptor compositions
|
|
MX2017015239A
(es)
*
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
|
GB201509413D0
(en)
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
CA2987290C
(en)
*
|
2015-06-10 |
2023-10-03 |
Nantkwest, Inc. |
Modified nk-92 cells for treating cancer
|
|
SG10201913682QA
(en)
|
2015-06-25 |
2020-03-30 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
MX2018001568A
(es)
|
2015-08-07 |
2019-04-25 |
Seattle Children´S Hospital Dba Seattle Children´S Res Institute |
Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
EP3355937A4
(en)
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
|
|
GB201518817D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
AU2016343722A1
(en)
|
2015-10-30 |
2018-05-24 |
Aleta Biotherapeutics, Inc. |
Targeted cancer therapy
|
|
GB201519900D0
(en)
*
|
2015-11-11 |
2015-12-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
JP2019513347A
(ja)
*
|
2016-03-04 |
2019-05-30 |
ノバルティス アーゲー |
複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用
|
|
WO2017193059A1
(en)
|
2016-05-06 |
2017-11-09 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
EP3458077A4
(en)
*
|
2016-05-17 |
2020-04-01 |
Chimera Bioengineering Inc. |
METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
|
|
EP4353750A3
(en)
*
|
2016-06-24 |
2024-07-24 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
CN117298260A
(zh)
*
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
GB2570063B
(en)
*
|
2016-09-09 |
2022-11-02 |
Crage Medical Co Ltd |
Fusion protein and applications thereof
|
|
US11219646B2
(en)
*
|
2016-09-30 |
2022-01-11 |
Baylor College Of Medicine |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
US20190352409A1
(en)
|
2016-11-11 |
2019-11-21 |
Autolus Limited |
Chimeric antigen receptor
|
|
AU2017363278B2
(en)
|
2016-11-22 |
2022-10-27 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
|
MX2019006631A
(es)
|
2016-12-12 |
2019-11-12 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
|
|
AU2018207300B2
(en)
*
|
2017-01-10 |
2023-08-24 |
The General Hospital Corporation |
T cells expressing a chimeric antigen receptor
|
|
WO2018144535A1
(en)
*
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
RU2019128544A
(ru)
|
2017-03-27 |
2021-04-28 |
Нэшнл Юниверсити Оф Сингапур |
Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
|
|
CN110636851B
(zh)
|
2017-03-27 |
2023-11-03 |
新加坡国立大学 |
截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
US11622977B2
(en)
*
|
2017-05-12 |
2023-04-11 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
AU2018270078A1
(en)
*
|
2017-05-15 |
2019-11-07 |
Autolus Limited |
A cell comprising a chimeric antigen receptor (CAR)
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
GB201707783D0
(en)
*
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
WO2019025800A1
(en)
*
|
2017-08-02 |
2019-02-07 |
Autolus Limited |
CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
|
|
CA3071282A1
(en)
|
2017-08-10 |
2019-02-14 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
CA3077174A1
(en)
|
2017-09-28 |
2019-04-04 |
Immpact-Bio Ltd. |
A universal platform for preparing an inhibitory chimeric antigen receptor (icar)
|
|
SG11202003258QA
(en)
*
|
2017-10-12 |
2020-05-28 |
Icell Gene Therapeutics Llc |
Compound chimeric antigen receptor (ccar) targeting multiple antigens, compositions and methods of use thereof
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
WO2019084240A1
(en)
|
2017-10-25 |
2019-05-02 |
Actinium Pharmaceuticals, Inc. |
METHODS OF TREATING CANCER USING RADIO-labeled CD45 ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELLULAR THERAPIES
|
|
DK3703750T3
(da)
|
2017-11-01 |
2025-02-10 |
Juno Therapeutics Inc |
Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
|
|
CA3089170A1
(en)
|
2018-02-09 |
2019-08-15 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
GB201803079D0
(en)
*
|
2018-02-26 |
2018-04-11 |
Autolus Ltd |
Cell
|
|
EP3743446A1
(en)
|
2018-03-12 |
2020-12-02 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
IL278348B2
(en)
|
2018-05-11 |
2025-03-01 |
Crispr Therapeutics Ag |
Methods and preparations for treating cancer
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
CA3099831A1
(en)
|
2018-05-15 |
2019-11-21 |
Autolus Limited |
Chimeric antigen receptor
|
|
CA3100386A1
(en)
|
2018-05-23 |
2019-11-28 |
National University Of Singapore |
Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
GB201813178D0
(en)
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
KR20210066865A
(ko)
|
2018-09-27 |
2021-06-07 |
오토러스 리미티드 |
키메라 항원 수용체
|
|
EP3632461A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
WO2020070290A1
(en)
|
2018-10-05 |
2020-04-09 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3860642A1
(en)
*
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632460A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816522D0
(en)
|
2018-10-10 |
2018-11-28 |
Autolus Ltd |
Methods and reagents for analysing nucleic acids from single cells
|
|
EP3873943A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
BR112021012172A2
(pt)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
Receptores de antígenos quiméricos e de célula t e métodos de uso
|
|
WO2020152197A1
(en)
|
2019-01-23 |
2020-07-30 |
Miltenyi Biotec B.V. & Co. KG |
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
SG11202109057XA
(en)
|
2019-03-05 |
2021-09-29 |
Nkarta Inc |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
JP7602475B2
(ja)
|
2019-03-08 |
2024-12-18 |
オートラス リミテッド |
操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
KR20220016083A
(ko)
|
2019-04-30 |
2022-02-08 |
센티 바이오사이언시스, 인코포레이티드 |
키메라 수용체 및 이의 사용 방법
|
|
SG11202111865UA
(en)
|
2019-05-01 |
2021-11-29 |
Pact Pharma Inc |
Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
|
|
EP3969482A1
(en)
*
|
2019-05-16 |
2022-03-23 |
University of Washington |
Lockr-mediated recruitment of car t cells
|
|
GB201909144D0
(en)
|
2019-06-25 |
2019-08-07 |
Autolus Ltd |
Culture medium
|
|
GB201910185D0
(en)
|
2019-07-16 |
2019-08-28 |
Autolus Ltd |
Method
|
|
US20220257757A1
(en)
|
2019-07-16 |
2022-08-18 |
Autolus Limited |
Method for preconditioning a subject who is about to receive a t-cell therapy
|
|
EP4017510A4
(en)
*
|
2019-08-20 |
2023-11-22 |
Senti Biosciences, Inc. |
CHIMERIC INHIBITOR RECEPTOR
|
|
WO2021044213A2
(en)
*
|
2019-09-05 |
2021-03-11 |
Migal-galilee Research Institute Ltd. |
Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
|
|
US20220401537A1
(en)
*
|
2019-09-16 |
2022-12-22 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
|
AU2020362554A1
(en)
*
|
2019-10-08 |
2022-05-12 |
Provincial Health Services Authority |
Chimeric cytokine receptors
|
|
US20220411535A1
(en)
*
|
2019-11-26 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for upregulating hla class i on tumor cells
|
|
PH12022551290A1
(en)
|
2019-11-26 |
2023-11-29 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
BR112022011399A2
(pt)
|
2019-12-11 |
2022-08-30 |
A2 Biotherapeutics Inc |
Receptor de antígeno quimérico baseado em lilrb1
|
|
US20230100000A1
(en)
|
2020-02-04 |
2023-03-30 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
EP4107174A4
(en)
*
|
2020-02-20 |
2024-10-30 |
Senti Biosciences, Inc. |
ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
|
|
WO2021168317A1
(en)
*
|
2020-02-20 |
2021-08-26 |
Senti Biosciences, Inc. |
Inhibitory chimeric receptor architectures
|
|
GB202007044D0
(en)
|
2020-05-13 |
2020-06-24 |
Autolus Ltd |
Method
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
GB202008957D0
(en)
|
2020-06-12 |
2020-07-29 |
Autolus Ltd |
Culture medium
|
|
CN116490518A
(zh)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
|
|
MX2023002041A
(es)
*
|
2020-08-20 |
2023-04-27 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para mesotelina.
|
|
HUE067417T2
(hu)
|
2020-08-20 |
2024-10-28 |
A2 Biotherapeutics Inc |
Készítmények és módszerek EGFR-pozitív rákok kezelésére
|
|
CN116724052A
(zh)
|
2020-08-20 |
2023-09-08 |
A2生物治疗股份有限公司 |
用于治疗ceacam阳性癌症的组合物和方法
|
|
US11976297B2
(en)
|
2020-09-21 |
2024-05-07 |
A2 Biotherapeutics, Inc. |
Engineered immune cells with receptor cross-talk
|
|
EP4228672A4
(en)
*
|
2020-10-15 |
2024-12-18 |
Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS FOR INHIBITING NATURAL KILLER CELL RECEPTOR
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
EP4294828A4
(en)
|
2021-02-16 |
2025-02-26 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATING HER2-POSITIVE CANCERS
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
US20240261332A1
(en)
*
|
2021-05-26 |
2024-08-08 |
Board Of Regents, The University Of Texas System |
Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
|
|
WO2023023602A1
(en)
*
|
2021-08-19 |
2023-02-23 |
Boan Boston Llc |
Fusion proteins for dephosphorylating proteins that regulate t cell activation through the tcr signaling pathway
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
US20250235477A1
(en)
|
2021-10-06 |
2025-07-24 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
WO2023218381A1
(en)
|
2022-05-11 |
2023-11-16 |
Autolus Limited |
Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
|
|
GB202209920D0
(en)
|
2022-07-06 |
2022-08-17 |
Autolus Ltd |
Cell
|
|
EP4602171A1
(en)
|
2022-10-15 |
2025-08-20 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
EP4520346A1
(en)
|
2023-09-06 |
2025-03-12 |
Gyncentrum Sp. z o.o. |
Cells, methods and systems for use in the treatment of a cancer with dual-car-t
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
WO2025250011A1
(en)
|
2024-05-29 |
2025-12-04 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Treatment for cancer
|